ArticleJournal of general internal medicine2016
Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey.
Article in Journal of general internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Influencers of generic drug utilization: A systematic review.Research in social & administrative pharmacy : RSAP · 2018Pooled it
- The Association Between Patient Sociodemographic Characteristics and Generic Drug Use: A Systematic Review and Meta-analysis.Journal of managed care & specialty pharmacy · 2018Pooled it
- Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial.Clinical pharmacology and therapeutics · 2019Trial
- Influence of sex and gender-related factors on the knowledge of generic medicines among older patients and caregivers.Internal and emergency medicine · 2026Article
- The perils of politeness: how large language models may amplify medical misinformation.NPJ digital medicine · 2025Article
- Prescription Use and Spending After the Introduction of a Real-Time Prescription Benefit Tool.JAMA network open · 2025Article
- Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024.Pharmacy (Basel, Switzerland) · 2025Article
- Increasing competition, improving access, and lowering the cost of naloxone in California.Health affairs scholar · 2025Article
- Knowledge and Perception of Consumers Towards Generic Medicines in Saudi Arabia: A Prospective Cross-Sectional Survey.Patient preference and adherence · 2025Article
- Choice intention for the national volume-based procurement drug and its associated factors: a cross-sectional study on patients with late-life depression in China.BMC psychiatry · 2024Article
- An exploration of factors influencing the selection of generic and innovator medicines in Saudi Arabia using an observational cross-sectional study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Clinical outcomes of generic versus brand-name clopidogrel for secondary prevention in patients with acute myocardial infarction: A nationwide cohort study.Clinical and translational science · 2023Article
- Article
- Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.JAMA internal medicine · 2022Article
- Retrospective Database Analysis to Explore Patterns and Economic Burden of Switchback to Brand After Generic or Authorized Generic Utilization.ClinicoEconomics and outcomes research : CEOR · 2022Article
- Patient Perceptions of Switching to a Generic Dry Powder Inhaler - Increased Understanding Through Journey Mapping.International journal of chronic obstructive pulmonary disease · 2022Article
- Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program.Circulation. Cardiovascular quality and outcomes · 2021Article
- Article
- Development and validation of prescription drug risk, efficacy, and benefit perception measures in the context of direct-to-consumer prescription drug advertising.Research in social & administrative pharmacy : RSAP · 2021Article
- Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.JAMA network open · 2021Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundOver 84 % of all prescriptions in the US are filled as generic drugs, though in prior surveys, patients reported concerns about their quality.
objectiveWe aimed to survey patients' perceptions and use of generic drugs.
designOur survey (administered August 2014) assessed patients' skepticism about generic drug safety and effectiveness and how often they requested brand-name drugs. Chi-square tests and two-sample t-tests assessed associations between patient demographics and the outcomes.
participantsOur sample frame was the CVS Advisor Panel, a national database of 124,621 CVS customers. We randomly selected 1450 patients with self-reported chronic conditions who filled at least one prescription in the prior 3 months. MAIN MEASURES: We assessed how often patients reported asking their physicians to prescribe a brand-name over a generic drug in the last year, and "generic skepticism," defined as not believing generic drugs were as safe, effective, had the same side effects, and contained the same active ingredients as brand-name drugs. KEY
resultsOf the 1,442 patients with valid addresses, 933 responded (65 % response rate) and 753 took the full survey. A vast majority (83 %) agreed that physicians should prescribe generic drugs when available, and 54 % said they had not asked their physicians to prescribe a brand-name drug over a generic in the past year. Most respondents considered generic drugs to be as effective (87 %) and safe (88 %) as their brand-name counterparts, and to have the same side effects (80 %) and active ingredients (84 %). Non-Caucasians were more likely than Caucasians to request a brand-name drug over a generic (56 % vs. 43 %, p < 0.01), and were also more skeptical of generic drugs' clinical equivalence (43 % vs. 29 %, p < 0.01).
conclusionsWe found a substantial shift towards more patients having positive views of generic drugs, but lingering negative perceptions will have to be overcome to ensure continued cost-savings and improved patient outcomes from generic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.